Evidence map›Paper›PMID 41341287›Full record

ArticleJAC-antimicrobial resistance2025

Rosario Huerto-Huánuco, Yaneth Quispe-Hualpa, Carla Andrea Alonso, Rosario Oporto-Llerena, Gabriela Soza, Zulema Surichaqui-Cerrón, Carmen Valera-Krumdieck, Luis Castañeda, Maria J Pons, Yolanda Sáenz and 2 more

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rosario Huerto-HuánucoGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Peru.ORCID https://orcid.org/0000-0001-6879-1951
Yaneth Quispe-HualpaGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Peru.
Carla Andrea AlonsoServicio de Análisis Clínicos, Laboratorio de Microbiología, Hospital San Pedro, Logroño, Spain.
Rosario Oporto-LlerenaGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Peru.
Gabriela SozaServicio de Microbiología, Instituto Nacional Materno Perinatal, Lima, Peru.
Zulema Surichaqui-CerrónGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Peru.
Carmen Valera-KrumdieckServicio de Patología Clínica, Área de Microbiología, Hospital Maria Auxiliadora, Lima, Peru.
Luis CastañedaFacultad de Ciencias de la Salud, Universidad Privada del Norte, Lima, Peru.
Maria J PonsGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Peru.
Yolanda SáenzÁrea de Microbiología Molecular, Centro de Investigación Biomédica de La Rioja, (CIBIR), Logroño, Spain.ORCID https://orcid.org/0000-0002-2457-4258
Joaquim RuizGrupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos-'One Health', Universidad Científica del Sur, Lima, Peru.ORCID https://orcid.org/0000-0002-4431-2036
Research Group on Acinetobacter spp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the synergistic activity of ampicillin/sulbactam plus ceftazidime/avibactam in a collection of carbapenem-resistant Materials and methods: One hundred and eighty-four CR- Results: High levels of resistance to ampicillin/sulbactam were found in the study. Thus, 1.1% (2/184), 11.4% (21/184) and 87.5% (161/184) of isolates were classified as susceptible, intermediate and resistant to ampicillin/sulbactam, respectively. Synergistic activity was observed in 97.2% of the non-susceptible CR- Conclusions: These findings demonstrate high levels of synergistic activity between ampicillin/sulbactam and ceftazidime/avibactam and their potential use as a treatment for CR-

Identifiers

PMID41341287
PMCPMC12669892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.